Circle Pharma

2026年9月17日美国生物制剂研发商Circle Pharma宣布完成F轮融资本轮融资由Euclidean Capital、The Column Group及礼来亚洲基金共同投资此次融资将主要用于推进Circle Pharma在细胞周期蛋白抑制剂领域的研发工作加速癌症治疗新药的临床开发Circle Pharma成立于2012年1月1日是一家专注于开发针对重要治疗靶标的内...

Circle Pharma has raised an oversubscribed $92.5 million Series E financing to advance CID-165, its first-in-class oral macrocyclic cyclin D1 RxL inhibitor, into clinical development for ER-positive breast cancer. The round was led by The Column Group, wi

Financing led by The Column Group with participation from Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly and Company CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, is expected to ent

SOUTH SAN FRANCISCO, Calif., September 16, 2026--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an oversubscribed $92.5 million Series E financing. Th

2026 FASEB cell cycle FINAL The post FASEB 2026: The Cyclin D1-CDK6 Complex Drives Resistance to the CDK4-Selective Inhibitor Atirmociclib in Estrogen Receptor-Positive Breast Cancer appeared first on Circle Pharma.

Discovery of Cell-Permeable Macrocyclic CyclinA/B RxL Inhibitors that Demonstrate Antitumor Activity The post Journal of Medicinal Chemistry: Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity appeared fi

Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with Rb-deficiency or hyperactivated E2F The post AACR 2026: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for

Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors The post AACR 2026: Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor,

Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: selective inhibitors of the RxL binding site of cyclin family proteins The post AACR 2026: Orally bioavailable peptide macrocycles disrupting intracellular prot